Interaction Checker
No Interaction Expected
Dolutegravir/Lamivudine (DTG/3TC)
Ciclosporin (Cyclosporine)
Quality of Evidence: Very Low
Summary:
Coadministration with dolutegravir/lamivudine has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciclosporin is metabolized by CYP3A4. Dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations. Coadministration of a dolutegravir containing regimen and ciclosporin was evaluated in a clinical study in which 19 transplant recipients with HIV (63% liver recipients) were switched from a raltegravir to a dolutegravir containing regimen (dolutegravir plus abacavir/lamivudine or lamivudine/tenofovir-DF) while on ciclosporin treatment. No participants experienced acute rejection or virological failure and CD4 cell counts remained unchanged during the follow-up. Pharmacokinetic data were available in 2 participants receiving ciclosporin. The switch in antiretroviral treatment did not result in clinically significant changes in ciclosporin Cmax, AUC and Cmin (-64%, -47% and +14%, respectively). No interaction is expected with lamivudine.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.